Serum levels of cytokines correlate to donor chimerism and acute graft-vs.-host disease after haematopoietic stem cell transplantation

European Journal of Haematology

Volumn 70, Issue 6, 2003, Pages 384-391

  Remberger, Mats ^a   Jaksch, Marie ^a   Uzunel, Mehmet ^a   Mattsson, Jonas ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

BMT; Chimerism; Cytokines; GVHD; SCT

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOKINE; FAS ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; METHOTREXATE; THYMOCYTE ANTIBODY; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CHILD; CHIMERA; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; FEMALE; GENETIC POLYMORPHISM; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKEMIA; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STATISTICAL ANALYSIS;

ACUTE DISEASE; ADOLESCENT; ADULT; ANTIGENS, CD95; CHILD; CHILD, PRESCHOOL; CYTOKINES; FEMALE; GENOTYPE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; T-LYMPHOCYTES; TRANSPLANTATION CHIMERA;

EID: 0037795749     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2003.00078.x     Document Type: Article

References (51)

1. THOMAS E, STORB R, CLIFT R, EEFER A, JOHNSON F, NEIMAN P, LERNER K, GLUCKSBERG H, BUCKNER C. Bonemarrow transplantation I and II. N Engl J Med 1975;292:832-843; 895-902.
2. RINGDÉN O, ZWAAN F, HERMANS J, GRATWOHL A. Transplantation for the Leukemia Working Party of the European Group for Bone Marrow Transplantation: European experience of bone marrow transplantation for leukemia. Transplant Proc 1987;19:2600.
3. BARRETT AJ, HOROWITZ MM, GALE RP, et al. Marrow transplantation for acute lymphoblastic leukemia: factors affecting relapse and survival. Blood 1989;74:862-871.
4. APPELBAUM FR, FISHER LD, THOMAS ED. Chemotherapy v marrow transplantation for adults with acute nonlymphocytic leukemia: a five-year follow-up. Blood 1988;72:179-184.
5. GIRALT SA, CHAMPLIN RE. Leukemia relapse after allogeneic bone marrow transplantation: a review. Blood 1994;84:3603-3612.
6. SPARRELID E, HÄGGLUND H, REMBERGER M, RINGDÉN O, LÖNNQVIST B, LJUNGMAN P, ANDERSSON J. Bacteraemia during the aplastic phase after allogeneic bone marrow transplantation is associated with early death from invasive fungal infection. Bone Marrow Transplant 1998;22:795-800.
7. STORB R, PRENTICE RL, BUCKNER CD, et al. Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment. N Engl J Med 1983;308:302-307.
8. GREBE S, STREILEIN J. Graft-versus-host reactions: a review. Advances in Immunology 1976;22:119-221.
9. ANTIN J, FERRARA J. Cytokine dysregulation and acute graft-versus-host disease. Blood 1992;80:2964-2968.
10. JADUS M, WEPISC H. The role of cytokines in graft-versus-host reaction and disease. Bone Marrow Transplant 1992;10:1-14.
11. KRENGER W, FERRARA JL. Dysregulation of cytokines during graft-versus-host disease. J Hematother 1996;5:3-14.
12. TESHIMA T, ORDEMANN R, REDDY P, GAGIN S, LIU C, COOKE KR, FERRARA JL. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nature Med 2002;8:575-581.
13. PIGUET PF, GRAU GE, ALLET B, VASSALLI P. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease. J Exp Med 1987;166:1280-1289.
14. HOLLER E, KOLB H, MÖLLER A, et al. Increased serum levels of tumor necrosis factor alfa precede major complications of bone marrow transplantation. Blood 1990;75:1011-1016.
15. REMBERGER M, RINGDÉN O, MARKLING L. TNFa levels are increased during bone marrow transplantation conditioning in patients who develop acute GVHD. Bone Marrow Transplant 1995;15:99-104.
16. NIEDERWIESER D, HEROLD M, WOLOSZCZUK W, AULITZKY W, MEISTER B, TILG H, GASTL G, BOWDEN R, HUBER C. Endogenous IFN-gamma during human bone marrow transplantation. Analysis of serum levels of interferon and interferon-dependent secondary messages. Transplantation 1990;50:620-625.
17. ALESSANDRINO EP, BERNASCONI P, COLOMBO A, BONI M, BONFICHI M, CALDERA D, BERNASCONI C. Levels of soluble low affinity IL2 receptors (s-IL2 R) and TNF in the serum after BMT. Bone Marrow Transplant 1991;7(suppl 2):51.
18. TIBERGHIEN P, RACADOT E, LIOURE B, DELAIN M, GIRARD A, WIJDENES J, PLOUVIER E, FLESCH M, CAHN JY, HERVE P. Soluble CD8, IL-2 receptor, and tumor necrosis factor-alpha levels in steroid-resistant acute graft-versus-host disease. Relation with subsequent response to anti-IL-2 receptor monoclonal antibody treatment. Transplantation 1991;52:475-480.
19. SYMINGTON F, SYMINGTON B, LIU P, VIGUET H, SANTHANAM U, SEHGAL P. The relationship of serum IL-6 levels to acute graft-versus-host disease and hepatorenal disease after human bone marrow transplantation. Transplantation 1992;54:457-462.
20. SCHWAIGHOFER H, HEROLD M, SCHWARZ T, NORDBERG J, CESKA M, PRIOR C, NACHBAUR D, WEYRER W, BRANKOVA J, EIBL B. Serum levels of interleukin 6 interleukin 8 and C-reactive protein after human allogeneic bone marrow transplantation. Transplantation 1994;58:430-436.
21. ROWBOTTOM A, RICHES P, DOWNIE C, HOBBS J. Monitoring cytokine production in peripheral blood during acute graft-versus-host disease following allogeneic bone marrow transplantation. Bone Marrow Transplant 1993;12:635-641.
22. NAKAMURA H, KOMATSU K, AYAKI M, et al. Serum levels of soluble IL-2 receptor, IL-12, IL-18, and IFN-gamma in patients with acute graft-versus-host disease after allogeneic bone marrow transplantation. J Allergy Clin Immunol 2000;106:S45-50.
23. IMOTO S, OOMOTO Y, MURATA K, et al. Kinetics of serum cytokines after allogeneic bone marrow transplantation: interleukin-5 as a potential marker of acute graft-versus-host disease. Int J Hematol 2000;72:92-97.
24. FUJIMORI Y, TAKATSUKA H, TAKEMOTO Y, HARA H, OKAMURA H, NAKANISHI K, KAKISHITA E. Elevated interleukin (IL)-I8 levels during acute graft-versus-host disease after allogeneic bone marrow transplantation. Br J Haematol 2000;109:652-657.
25. MCCARTHY P, ABHYANKAR S, NEBEN S, NEWMAN G, SIEFF C, THOMMSON R, BURAKOFF S, FERRARA JLM. Inhibition of interleukin 1 by an interleukin 1 receptor antagonist prevents graft-versus-host disease. Blood 1991;78:1915-1918.
26. ANASETTI C, MARTIN PJ, STORB R, et al. Prophylaxis of graft-versus-host disease by administration of the murine anti-IL-2 receptor antibody 2A3. Bone Marrow Transplant 1991;7:375-381.
27. MATTSSON J, UZUNEL M, REMBERGER M, RINGDEN O. T cell mixed chimerism is significantly correlated to a decreased risk of acute graft-versus-host disease after allogeneic stem cell transplantation. Transplantation 2001;71:433-439.
28. OLERUP O, ZETTERQVIST H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours. An alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992;39:225-235.
29. RINGDÉN O, REMBERGER M, PERSSON U, et al. Similar incidence of graft-versus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings. Bone Marrow Transplant 1995;15:619-625.
30. RINGDÉN O, BÄCKMAN L, LÖNNQVIST B, HEIMDAHL A, LINDHOLM A, BOLME P, GAHRTON G. A randomized trial comparing use of cyclosporine and methotrexate for graft-versus-host disease prophylaxis in bone marrow transplant recipients with haematological malignancies. Bone Marrow Transplant 1986;1:41-51.
31. STORB R, DEEG H, WHITEHEAD J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft-versus-host disease after marrow transplantation for leukemia. N Engl J Med 1986;314:729-735.
32. RINGDÉN O, PIHLSTEDT P, MARKLING L, ASCHAN J, BÅRYD I, LJUNGMAN P, LÖNNQVIST B, TOLLEMAR J, JANOSSY G, SUNDBERG B. Prevention of graft-versus-host disease with T-cell depletion or cyclosporin and methotrexate. A randomized trial in adult leukemic marrow recipients. Bone Marrow Transplant 1991;7:221-226.
33. GLUCKSBERG H, STORB R, FEFER A, BUCKNER C, NEIMAN P, CLIFT R, LERNER K, THOMAS E. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974;18:295-304.
34. RINGDÉN O. Management of graft-versus-host disease. Eur J Haematol 1993;51:1-12.
35. MATTSSON J, UZUNEL M, TAMMIK L, ASCHAN J, RINGDÉN O. Leukemia lineage-specific chimerism analysis is a sensitive predictor of relapse in patients with acute myeloid leukemia and myelodysplastic syndrome after allogeneic stem cell transplantation. Leukemia 2001;15:1976-1985.
36. ZETTERQUIST H, MATTSSON J, UZUNEL M, NÄSMAN-BJÖRK I, SVENBERG P, TAMMIK L, BAYAT G, WINIARSKI J, RINGDEN O. Mixed chimerism in the B cell lineage is a rapid and sensitive indicator of minimal residual disease in bone marrow transplant recipients with pre-B cell acute lymphoblastic leukemia. Bone Marrow Transplant 2000;25:843-851.
37. CAVET J, MIDDLETON PG, SEGALL M, NOREEN H, DAVIES SM, DICKINSON AM. Recipient tumor necrosis factor-alpha and interleukin-10 gene polymorphisms associate with early mortality and acute graft-versus-host disease severity in HLA-matched sibling bone marrow transplants. Blood 1999;94:3941-3946.
38. WILSON AG, DI GIOVINE FS, BLAKEMORE AI, DUFF GW. Single base polymorphism in the human tumour necrosis factor alpha (TNF alpha) gene detectable by Ncol restriction of PCR product. Human Mol Genet 1992;1:353.
39. KRENGER W, FERRARA JL. Graft-versus-host disease and the Th1/Th2 paradigm. Immunol Res 1996;15:50-73.
40. FIORENTINO D, ZLOTNIK A, MOSMANN T, HOWARD M, O'GARRA A. IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991;147:3815-3822.
41. ESPINOZA-DELGADO I, BOSCO MC, MUSSO T, MOOD K, RUSCETTI FW, LONGO DL, VARESIO L. Inhibitory cytokine circuits involving transforming growth factor-beta, interferon-gamma, and interleukin-2 in human monocyte activation. Blood 1994;83:3332-3338.
42. BACCHETTA R, BIGLER M, TOURAINE J, PARKMAN R, TOVO PA, ABRAMS J, DE WAAL MALEFYT R, DE VRIES JE, RONCAROLO HG. High levels of IL-10 production in vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoetic stem cells. J Exp Med 1994;179:493-502.
43. LIEM LM, FIBBE WE, VAN HOUWELINGEN HC, GOULMY E. Serum transforming growth factor-betal levels in bone marrow transplant recipients correlate with blood cell counts and chronic graft-versus-host disease. Transplantation 1999;67:59-65.
44. HEMPEL L, KORHOLZ D, NUSSBAUM P, BONIG H, BURDACH S, ZINTL F. High interleukin-10 serum levels are associated with fatal outcome in patients after bone marrow transplantation. Bone Marrow Transplant 1997;20:365-368.
45. REMBERGER M, RINGDÉN O. Serum levels of cytokines after bone marrow transplantation; Increased IL-8 levels during veno-occlusive disease of the liver. Eur J Haematol 1997;59:254-262.
46. LIEM LM, VAN HOUWELINGEN HC, GOULMY E. Serum cytokine levels after HLA-identical bone marrow transplantation. Transplantation 1998;66:863-871.
47. TURNER DM, GRANT SCD, LAMB WR, BRENCHLEY PEC, DYER PA, SINNOTT PJ, HUTCHINSON IV. A genetic marker of high TNFalpha production in heart transplant recipients. Transplantation 1995;60:1113-1117.
48. MIDDLETON PG, TAYLOR PRA, JACKSON G, PROCTOR SJ, DICKINSON AM. Cytokine gene polymorphism associating with severe acute graft-versus-host disease in HLA-identical sibling transplants. Blood 1998;92:3943-3948.
49. NORDLANDER A, UZUNEL M, MATTSSON J, REMBERGER M. The TNFd4 allele is correlated to moderate-to-severe acute graft-versus-host disease after allogeneic stem cell transplantation. Br J Haemat 2002;119:1133-1136.
50. VIA CS, NGUYEN P, SHUSTOV A, DRAPPA J, ELKON KB. A major role for the Fas pathway in acute graft-versus-host disease. J Immunol 1996;157:5387-5393.
51. BAKER MB, RILEY RL, PODACK ER, LEVY RB. Graft-versus-host-disease-associated lymphoid hypoplasia and B cell dysfunction is dependent upon donor T cell-mediated Fas-ligand function, but not perforin function. Proc Natl Acad Sci USA 1997;94:1366-1371.